Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 5/20 | 0.51 |
| ▸ | KLK1 | P06870 | 4/20 | 0.51 |
| ▸ | KLK6 | Q92876 | 4/20 | 0.51 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 7/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | F9 | P00740 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21350543 | 0.85 | CRHBP (0.55) | XIAPBIRC2MAPTNPC1RAB9A | |
| SCHEMBL2642980 | 0.84 | CA12 (0.57) | PLGKLK1KLK6MAPTF9 | |
| SCHEMBL12285446 | 0.84 | PLG (0.44) | PLGKLK1KLK6KLKB1PKM | |
| SCHEMBL22593900 | 0.83 | MAPT (0.60) | XIAPBIRC2MAPTNPC1RAB9A | |
| SCHEMBL14435680 | 0.83 | XIAP (0.48) | XIAPBIRC2MAPTPKMNPC1 | |
| SCHEMBL24086454 | 0.83 | MAPT (0.60) | XIAPBIRC2MAPTNPC1RAB9A | |
| SCHEMBL21229646 | 0.81 | SMN1; SMN2 (0.47) | XIAPBIRC2MAPTNPC1RAB9A | |
| SCHEMBL20150736 | 0.80 | MAPT (0.67) | XIAPBIRC2MAPTNPC1RAB9A | |
| SCHEMBL12677519 | 0.80 | CA1 (0.63) | PLGKLK1KLK6NPC1RAB9A | |
| SCHEMBL12205991 | 0.80 | CA1 (0.63) | PLGKLK1KLK6NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190328899-A1 | AMANITIN ANTIBODY CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2019-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190328899-A1 | AMANITIN ANTIBODY CONJUGATES | B2M, CD22, ADM2 | PLG 2243/4885KLK1 1929/4885KLK6 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.